Jubilant Life Sciences’ arm eyeing to acquire speciality pharma business in USA

21 Mar 2017 Evaluate

Jubilant Life Sciences’ material wholly owned subsidiary in Singapore - Jubilant Pharma (JPL) has received an approval to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The board of directors of JPL at its meeting has approved for the same.

The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL’s existing business, if it materializes.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.

Jubilant Pharmova Share Price

831.80 -18.65 (-2.19%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×